Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 4606Pancreatic Neoplasms 2845Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Colonic Neoplasms 1791Rectal Neoplasms 1720Esophageal Neoplasms 1376Liver Neoplasms 921Neoplasms 915Breast Neoplasms 839Neoplasm Metastasis 765Carcinoma, Non-Small-Cell Lung 707Cholangiocarcinoma 587Lung Neoplasms 557Ovarian Neoplasms 535Esophageal Squamous Cell Carcinoma 514Gastrointestinal Neoplasms 495Melanoma 381Prostatic Neoplasms 373Biliary Tract Neoplasms 373Head and Neck Neoplasms 303Uterine Cervical Neoplasms 288Carcinoma, Renal Cell 284Adenocarcinoma Of Esophagus 273Squamous Cell Carcinoma of Head and Neck 264Sarcoma 264Gastrointestinal Stromal Tumors 252Endometrial Neoplasms 235Urinary Bladder Neoplasms 226Gallbladder Neoplasms 225

Interventions

Nivolumab 2pembrolizumab 1folfirinox 1durvalumab 1Trastuzumab 1Single Person 1Paclitaxel 1Irinotecan 1IFL protocol 1Folfox protocol 1Docetaxel 1Carboplatin 1((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Gastroesophageal Adenocarcinoma × Gastrointestinal × Clear all
NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

University of California, Irvine

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT04021108 2025-06-24

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Weill Medical College of Cornell University

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT05986227 2023-08-14

SCORPIO

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
126 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT00073502 2006-02-22

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

OSI Pharmaceuticals

Phase 2 Completed
43 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡